Antonio Britto, the executive president of Interfarma, the main association gathering together local and international innovators in Brazil, provides insights into some of the hottest topics in Brazil’s pharmaceutical sector, including an assessment of the eye-catching growth prospects of the industry after years of political and economy turmoil, as well as the judicialization of health, technology transfers, and the necessity to build a new model for innovation access.
Amidst political and economic turmoil that saw the Brazilian economy contracting 3.8 percent in 2015 and 3.6 percent in 2016, the pharmaceutical industry stands as one of the only sectors of the Brazilian economy that has continued to grow and develop itself. How do you explain this specificity and what is your assessment of the growth prospects for innovators in Brazil moving forward?
"Accessing medicines through legal actions comes at a very high cost for the Ministry of Health and does not stand a sustainable way to provide access to medicines."
